General description
INN
Vancomycin
Medicine type
Chemical agent
Antibiotic groups
EML status history
First added in 1995
(TRS
867)
for
Methicillin resistant Staphylococcus aureus
Added in 2017
(TRS
1006)
for
Neutropenia
Added in 2017
(TRS
1006)
for
Intestinal infections due to Clostridioides difficile
Removed in 2017
(TRS
1006)
for
Methicillin resistant Staphylococcus aureus
Added in 2021
(TRS
1035)
for
Endophthalmitis
Added in 2021
(TRS
1035)
for
Necrotising fasciitis
Wikipedia
DrugBank
Recommendations
Section
Watch group antibiotics
- Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection
Indications
First choice
Necrotising fasciitis co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis
Other indications